Is NNC0165-1875 legal in the United Kingdom?

The clearest test of stacking a second appetite hormone onto semaglutide, and it failed on both counts. The authors call the added effect modest and not clinically meaningful, and the higher dose was not tolerated.

Peptide YY is the gut hormone that tells your brain the meal is over, acting through a different receptor from GLP-1. On paper it is the obvious partner: two independent satiety pathways should add up.

Mechanism: A long-acting analogue of PYY(3-36), the truncated form of peptide YY released from L cells in the distal gut after eating. PYY(3-36) is selective for the Y2 receptor, which is presynaptic and inhibitory on hypothalamic neuropeptide Y neurons, reducing the orexigenic drive.

Regulatory history: Investigational. Not approved. Phase 2 completed with a result its own authors describe as not clinically meaningful.

Licenses medicines for the UK market. A compound without a marketing authorisation is an unlicensed medicine, which can only lawfully be supplied for human use through a prescriber under the specials scheme, not sold as a research product.

The classification above is the The Longevity Archive reading of Medicines and Healthcare products Regulatory Agency listings for NNC0165-1875 at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.